Equities

medmix AG

medmix AG

Actions
Health CareMedical Equipment and Services
  • Price (CHF)8.64
  • Today's Change-0.25 / -2.81%
  • Shares traded46.97k
  • 1 Year change-54.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 16:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medmix Systems AG is a Switzerland-based company active in manufacturing of high-precision delivery devices. The Company operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.

  • Revenue in CHF (TTM)479.70m
  • Net income in CHF-1.80m
  • Incorporated2021
  • Employees2.70k
  • Location
    medmix AGNeuhofstrasse 20BAAR 6340SwitzerlandCHE
  • Phone+41 417237300
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Detection Technology Oyj-92.88bn-92.88bn189.21m464.00--2.76----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
BICO Group AB180.57m-63.08m191.71m828.00--0.8285--1.06-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Onward Medical NV0.00-32.65m193.16m99.00--7.67-----1.09-1.090.000.60790.00----0.00-66.40-55.70-79.20-61.60-------79,513.95----0.4855---34.62---10.40--32.59--
Medistim ASA43.81m8.14m207.07m152.0025.416.3720.424.735.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
Tristel Plc46.81m7.24m234.16m213.0032.606.4522.815.000.1350.1350.87140.68180.98121.815.74--15.189.3217.7510.7680.0880.7515.4711.093.04--0.1532109.3516.459.8945.469.9910.1319.53
Nyxoah SA4.72m-49.21m252.11m147.00--2.59--53.41-1.72-1.720.1663.040.03660.55692.3034,618.53-38.20-23.73-42.88-25.9861.7562.42-1,042.52-1,469.594.95-45.270.1822--40.99---38.39--100.58--
COLTENE Holding AG238.80m12.34m299.97m1.19k24.353.0015.621.262.062.0639.8916.731.271.386.06198,668.906.5510.4811.7018.7464.9062.685.177.470.861910.180.342179.94-9.133.54-54.05-6.81-7.72-7.79
Guerbet SA767.39m30.43m308.78m2.92k10.480.85333.720.40242.512.5166.4230.820.81280.54935.56282,958.603.031.404.961.8678.5876.023.731.821.163.850.507357.824.30-0.0993158.05-12.615.23-10.07
Stratec SE232.69m9.30m312.79m1.46k33.631.4811.501.340.82360.823620.6118.740.56051.275.32164,609.702.247.072.858.2027.0427.324.009.700.92693.860.401140.81-4.636.88-55.293.30-2.16-7.68
Synektik SA133.60m18.10m318.79m164.0017.627.7615.252.399.929.9273.2522.521.8426.956.41--24.9815.0939.9723.8326.8224.8813.5511.001.4945.180.109--39.8235.9061.3656.0850.89--
IVF Hartmann Holding AG152.90m17.64m350.40m298.0019.862.4814.962.297.357.3563.7258.840.87883.148.52502,947.4010.147.2912.068.9055.2153.2911.548.303.95--0.005852.16-1.792.0934.951.49-14.8326.82
medmix AG479.70m-1.80m356.51m2.70k--0.76466.190.7432-0.05-0.0511.3511.300.47783.405.58180,474.00-0.09962.06-0.12272.4932.5836.38-0.20854.161.062.210.436167.701.991.40-97.41-64.3612.01--
Ion Beam Applications SA432.58m7.29m371.25m1.84k49.104.2720.390.85820.26890.268915.993.090.77212.152.70234,517.101.301.556.014.3234.1935.231.692.380.63723.770.399264.8318.6710.74-250.40---8.06--
CellaVision AB59.10m12.04m410.15m228.0034.066.6626.676.946.306.3030.9132.190.78491.917.263,233,162.0015.9915.3018.4518.2466.9969.0320.3819.982.151,358.860.044110.185.9413.1710.128.0030.458.45
RaySearch Laboratories AB (publ)93.72m14.03m426.08m414.0039.118.4412.774.555.105.1034.0923.650.60235.513.293,005,152.009.021.2913.691.8891.0690.5714.972.551.27108.610.370669.0021.1610.26243.060.7648-1.31--
Advanced Medical Solutions Group plc146.35m12.43m497.15m1.50k40.091.8319.833.400.0510.0510.60111.120.39771.704.91154,244.703.386.543.647.0654.4556.758.4914.826.80--0.270225.851.514.23-22.14-6.7115.6612.32
Data as of Nov 21 2024. Currency figures normalised to medmix AG's reporting currency: Swiss Franc CHF

Institutional shareholders

19.85%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 18 Aug 20231.25m3.03%
Credit Suisse Asset Management (Schweiz) AGas of 09 Mar 20231.23m2.99%
UBS Asset Management Switzerland AGas of 26 Jan 20241.23m2.99%
Fidelity Investments Canada ULCas of 30 Sep 20241.10m2.68%
Harris Associates LPas of 30 Sep 2024957.00k2.32%
The Vanguard Group, Inc.as of 06 Nov 2024857.09k2.08%
Oddo BHF Asset Management SASas of 31 Oct 2024576.76k1.40%
Dimensional Fund Advisors LPas of 07 Nov 2024376.23k0.91%
Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024302.02k0.73%
Capital Research & Management Co. (Global Investors)as of 30 Sep 2024299.73k0.73%
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.